Observational studyScientific reports2025
Association of serum copper, zinc and copper to zinc ratio in patients with acute myeloid leukemia.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Acute myeloid leukemia (AML) is a rare hematological disorder that has detrimental effects on human health and requires the exploration of biomarkers for diagnosis and prognostic evaluation. Essential trace elements like copper (Cu) and zinc (Zn) play diverse biological functions, however, limited data are available regarding their role in AML. The present study aimed to determine the serum levels of Cu and Zn, and assess the serum Cu/Zn ratio (SCZR) in newly diagnosed adult AML cases. This observational case-control study included 50 adult AML patients and 50 healthy controls. Blood samples were collected to analyze complete blood count (CBC), serum levels of Cu and Zn were determined by an atomic absorption spectrophotometer. The study showed significant hematological abnormalities in AML, including anemia (reduced hemoglobin/hematocrit levels), leukocytosis (elevated WBC counts), and thrombocytopenia (low platelet counts). Compared to controls, AML patients exhibited significantly higher (p = < 0.05) serum Cu levels (2.01 ± 0.87 mg/L), lower Zn levels (1.02 ± 0.54 mg/L), and an elevated SCZR (2.74 ± 2.31). Furthermore, higher blast counts (> 40%) were significantly associated (p = 0.005) with reduced Zn levels (0.82 ± 0.37 mg/L), and shorter survival episodes (9.51 ± 3.93 months; p = 0.001). A moderate-to-strong inverse correlation was observed between blast counts (> 40%) and survival duration (p = 0.001). The study demonstrated significant differences in serum Cu, Zn, and SCZR between AML patients and controls. Particularly, reduced serum Zn was linked to higher blast counts, whereas serum Cu and SCZR showed no association with blast burden. These findings highlight the prognostic relevance of blast burden and trace element dysregulation in AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.